IL122398A - A process for regulating the silylation of proteins produced by mammalian cell cultures - Google Patents

A process for regulating the silylation of proteins produced by mammalian cell cultures

Info

Publication number: IL122398A
Authority: IL; Israel
Prior art keywords: cell; culture; tnfrl; iggi; host cell
Prior art date: 1995-06-06

Application number

IL12239896A

Other languages

English (en)

Hebrew (he)

Other versions

IL122398A0 (en

Original Assignee

Genentech Inc

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1996-06-06

Publication date

2001-12-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23863440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-06 Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc

1998-06-15 Publication of IL122398A0 publication Critical patent/IL122398A0/xx

2001-12-23 Publication of IL122398A publication Critical patent/IL122398A/en

Links

238000000034 method Methods 0.000 title claims abstract description 113
238000004113 cell culture Methods 0.000 title claims abstract description 83
230000008569 process Effects 0.000 title claims abstract description 78
108090000623 proteins and genes Proteins 0.000 title claims description 72
102000004169 proteins and genes Human genes 0.000 title claims description 64
210000004962 mammalian cell Anatomy 0.000 title description 31
230000009450 sialylation Effects 0.000 title description 9
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 84
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 82
102000003886 Glycoproteins Human genes 0.000 claims abstract description 74
108090000288 Glycoproteins Proteins 0.000 claims abstract description 74
238000004519 manufacturing process Methods 0.000 claims abstract description 70
239000002253 acid Substances 0.000 claims abstract description 30
150000002482 oligosaccharides Polymers 0.000 claims abstract description 25
150000003839 salts Chemical class 0.000 claims abstract description 25
238000012258 culturing Methods 0.000 claims abstract description 21
210000004027 cell Anatomy 0.000 claims description 166
238000002360 preparation method Methods 0.000 claims description 47
239000000203 mixture Substances 0.000 claims description 25
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 23
230000003698 anagen phase Effects 0.000 claims description 14
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 11
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 11
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
230000010261 cell growth Effects 0.000 claims description 10
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 10
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 9
230000003247 decreasing effect Effects 0.000 claims description 9
108020001507 fusion proteins Proteins 0.000 claims description 9
102000037865 fusion proteins Human genes 0.000 claims description 9
239000002299 complementary DNA Substances 0.000 claims description 7
229950006780 n-acetylglucosamine Drugs 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
239000013598 vector Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims 6
108060003951 Immunoglobulin Proteins 0.000 claims 2
102000018358 immunoglobulin Human genes 0.000 claims 2
235000018102 proteins Nutrition 0.000 description 60
235000002639 sodium chloride Nutrition 0.000 description 27
239000001963 growth medium Substances 0.000 description 25
150000001720 carbohydrates Chemical group 0.000 description 24
235000014633 carbohydrates Nutrition 0.000 description 24
239000000047 product Substances 0.000 description 24
239000002609 medium Substances 0.000 description 20
108090000765 processed proteins & peptides Proteins 0.000 description 20
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 17
230000012010 growth Effects 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 16
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 14
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 14
229920001542 oligosaccharide Polymers 0.000 description 14
229920001184 polypeptide Polymers 0.000 description 14
102000003298 tumor necrosis factor receptor Human genes 0.000 description 14
102100040247 Tumor necrosis factor Human genes 0.000 description 13
230000001276 controlling effect Effects 0.000 description 13
238000013518 transcription Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
101150009046 Tnfrsf1a gene Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
230000000694 effects Effects 0.000 description 11
125000005629 sialic acid group Chemical group 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 9
239000001888 Peptone Substances 0.000 description 9
108010080698 Peptones Proteins 0.000 description 9
239000008103 glucose Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
150000002772 monosaccharides Chemical class 0.000 description 9
235000015097 nutrients Nutrition 0.000 description 9
235000019319 peptone Nutrition 0.000 description 9
230000007704 transition Effects 0.000 description 9
239000000306 component Substances 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
230000014616 translation Effects 0.000 description 7
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
150000008163 sugars Chemical class 0.000 description 6
229940104230 thymidine Drugs 0.000 description 6
239000011573 trace mineral Substances 0.000 description 6
235000013619 trace mineral Nutrition 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
102000003838 Sialyltransferases Human genes 0.000 description 5
108090000141 Sialyltransferases Proteins 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
102000005348 Neuraminidase Human genes 0.000 description 4
108010006232 Neuraminidase Proteins 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
238000005571 anion exchange chromatography Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000012511 carbohydrate analysis Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
210000003292 kidney cell Anatomy 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000001890 transfection Methods 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102100024746 Dihydrofolate reductase Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
101000976075 Homo sapiens Insulin Proteins 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
244000000188 Vaccinium ovalifolium Species 0.000 description 3
239000000654 additive Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
238000011098 chromatofocusing Methods 0.000 description 3
108020001096 dihydrofolate reductase Proteins 0.000 description 3
PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
238000001030 gas--liquid chromatography Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 2
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000021120 animal protein Nutrition 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003729 cation exchange resin Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
150000002337 glycosamines Chemical class 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
150000002484 inorganic compounds Chemical class 0.000 description 2
229910010272 inorganic material Inorganic materials 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000002523 lectin Substances 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000012092 media component Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
LHZGINQTXBBMKG-PYHIIVFHSA-N (4S,5R,6R)-5-amino-2,4-dihydroxy-5-(2-hydroxyacetyl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound OCC(=O)[C@@]1(N)[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO LHZGINQTXBBMKG-PYHIIVFHSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101000959414 Bacillus thermoamyloliquefaciens Alpha-glucosidase 2 Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000013585 Bombesin Human genes 0.000 description 1
108010051479 Bombesin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
108010009575 CD55 Antigens Proteins 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
206010012422 Derealisation Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
108010059881 Lactase Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010031099 Mannose Receptor Proteins 0.000 description 1
102000001696 Mannosidases Human genes 0.000 description 1
108010054377 Mannosidases Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
FDJKUWYYUZCUJX-PGIATKPXSA-M N-glycoloylneuraminate Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C([O-])=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-M 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
108010004434 Primatone RL Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102400000834 Relaxin A chain Human genes 0.000 description 1
101800000074 Relaxin A chain Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
241000583281 Sugiura Species 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
239000000868 anti-mullerian hormone Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000007068 beta-elimination reaction Methods 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000010364 biochemical engineering Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000004320 controlled atmosphere Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000006353 environmental stress Effects 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012527 feed solution Substances 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010042430 galactose receptor Proteins 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
108010050669 glucosidase I Proteins 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
102000028416 insulin-like growth factor binding Human genes 0.000 description 1
108091022911 insulin-like growth factor binding Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229940116108 lactase Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
229940066294 lung surfactant Drugs 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012577 media supplement Substances 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
-1 oligosaccharide carbohydrate Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
108010066381 preproinsulin Proteins 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000013587 production medium Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
108010087851 prorelaxin Proteins 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
125000005630 sialyl group Chemical group 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940087562 sodium acetate trihydrate Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000013337 sub-cultivation Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL12239896A 1995-06-06 1996-06-06 A process for regulating the silylation of proteins produced by mammalian cell cultures IL122398A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/469,348 US5705364A (en)	1995-06-06	1995-06-06	Mammalian cell culture process
PCT/US1996/009284 WO1996039488A1 (en)	1995-06-06	1996-06-06	Process for controlling sialylation of proteins produced by mammalian cell culture

Publications (2)

Publication Number	Publication Date
IL122398A0 IL122398A0 (en)	1998-06-15
IL122398A true IL122398A (en)	2001-12-23

Family

ID=23863440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12239896A IL122398A (en)	1995-06-06	1996-06-06	A process for regulating the silylation of proteins produced by mammalian cell cultures

Country Status (35)

Country	Link
US (1)	US5705364A (es)
EP (2)	EP0832189B2 (es)
JP (2)	JPH11507523A (es)
KR (1)	KR100496356B1 (es)
CN (1)	CN1166772C (es)
AR (2)	AR004940A1 (es)
AT (2)	ATE302266T1 (es)
AU (1)	AU717847B2 (es)
BG (1)	BG63213B1 (es)
BR (1)	BR9609150A (es)
CA (1)	CA2220684C (es)
CZ (1)	CZ293719B6 (es)
DE (2)	DE69637867D1 (es)
DK (2)	DK1609853T4 (es)
EA (1)	EA001215B1 (es)
ES (2)	ES2248812T5 (es)
GE (1)	GEP20012519B (es)
HU (1)	HU226420B1 (es)
IL (1)	IL122398A (es)
IS (1)	IS2614B (es)
MY (1)	MY113496A (es)
NO (1)	NO322276B1 (es)
NZ (1)	NZ310202A (es)
OA (1)	OA10753A (es)
PL (1)	PL185484B1 (es)
PT (1)	PT1609853E (es)
RO (1)	RO120267B1 (es)
SA (1)	SA96170351B1 (es)
SI (2)	SI0832189T2 (es)
SK (1)	SK282658B6 (es)
TR (1)	TR199701543T1 (es)
TW (2)	TW516962B (es)
UA (1)	UA47428C2 (es)
WO (1)	WO1996039488A1 (es)
ZA (1)	ZA964776B (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE236249T1 (de)	1989-09-12	2003-04-15	Hoffmann La Roche	Tfn-bindende proteine
US6656466B1 (en) *	1995-06-06	2003-12-02	Genetech, Inc.	Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) †	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
JP4306813B2 (ja)	1995-09-19	2009-08-05	アスビオファーマ株式会社	動物細胞の新規培養方法
HRP970224A2 (en) *	1996-05-08	1998-04-30	Hoffmann La Roche	TREATMENT OF ASTHMA WITH TNFR-Ig
AU2051899A (en) *	1997-12-03	1999-06-16	Roche Diagnostics Gmbh	Method for preparing polypeptides with appropriate glycosilation
US6140445A (en) *	1998-04-17	2000-10-31	Crompton Corporation	Silane functional oligomer
ATE314485T1 (de) *	1998-05-29	2006-01-15	Genentech Inc	Zellkulturverfahren für die produktion von glycoproteinen
US6528286B1 (en) *	1998-05-29	2003-03-04	Genentech, Inc.	Mammalian cell culture process for producing glycoproteins
TR200504220T2 (tr)	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
GB9828624D0 (en) *	1998-12-23	1999-02-17	Glaxo Group Ltd	Production of proteins
KR100475417B1 (ko) *	1998-12-30	2005-07-18	씨제이 주식회사	시알산 함량이 높은 재조합 당단백질의 제조방법
US7294481B1 (en) *	1999-01-05	2007-11-13	Immunex Corporation	Method for producing recombinant proteins
PT1171615E (pt)	1999-04-26	2007-03-30	Genentech Inc	Processo de cultura celular para glicoproteínas
US6261805B1 (en) *	1999-07-15	2001-07-17	Boyce Thompson Institute For Plant Research, Inc.	Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
KR100394474B1 (ko) *	1999-12-18	2003-08-09	동아제약 주식회사	동물세포에서 재조합 당단백질의 연속식 대량생산 방법
DE60116137T2 (de) *	2000-05-16	2006-08-24	Lipoxen Technologies Ltd.	Derivatisierung von proteinen in wässrigem lösungsmittel
US20030170813A1 (en) *	2000-07-05	2003-09-11	Kenichi Suga	Process for producing glycoprotein
US20030040095A1 (en) *	2001-03-16	2003-02-27	Achille Arini	Method for the production of pharmaceutically active recombinant proteins
JP2004532642A (ja) *	2001-06-13	2004-10-28	ジェネンテック・インコーポレーテッド	動物細胞の培養方法と動物細胞でのポリペプチド産生
CA2480121C (en) *	2002-03-27	2012-02-28	Immunex Corporation	Methods for increasing polypeptide production
US20030190710A1 (en) *	2002-03-28	2003-10-09	Devries Ruth L.	Control of glycoforms in IgG
US6924124B1 (en) *	2002-08-23	2005-08-02	Immunex Corporation	Feeding strategies for cell culture
US7067279B1 (en)	2002-08-23	2006-06-27	Immunex Corporation	Cell culture performance with betaine
US6974681B1 (en)	2002-08-23	2005-12-13	Immunex Corporation	Cell culture performance with vanadate
EP1578799B8 (en) *	2002-12-02	2011-03-23	Amgen Fremont Inc.	Antibodies directed to tumor necrosis factor and uses thereof
PL377731A1 (pl) *	2002-12-23	2006-02-06	Bristol-Myers Squibb Company	Sposoby hodowli komórek ssaczych do wytwarzania białka
ATE488600T1 (de) *	2002-12-23	2010-12-15	Bristol Myers Squibb Co	Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2522779A1 (en) *	2003-04-25	2004-11-11	Immunex Corporation	Inducers of recombinant protein expression
EP1959011B1 (en)	2003-10-24	2012-03-28	Selexis S.A.	High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of matrix attachment region sequences
CA2548940A1 (en) *	2003-12-23	2005-07-14	Applied Research Systems Ars Holding N.V.	Process for the production of tumor necrosis factor-binding proteins
EP1709185A1 (en) *	2003-12-31	2006-10-11	Samyang Genex Corporation	Method for mass production of secondary metabolites in plant cell culture by treatment of an alkanoic acid or salt thereof
JP4913604B2 (ja) *	2004-02-13	2012-04-11	グリコトープゲーエムベーハー	高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI374935B (en) *	2004-08-27	2012-10-21	Pfizer Ireland Pharmaceuticals	Production of α-abeta
TWI364458B (en) *	2004-08-27	2012-05-21	Wyeth Res Ireland Ltd	Production of tnfr-lg
TWI384069B (zh) *	2004-08-27	2013-02-01	Pfizer Ireland Pharmaceuticals	多胜肽之製法
US8858935B2 (en) *	2005-05-19	2014-10-14	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
AU2006254217A1 (en) *	2005-06-03	2006-12-07	Biovitrum Ab (Publ)	Process for cultivating animal cells comprising the feeding of plant-derived peptones
KR100670105B1 (ko)	2005-06-29	2007-01-17	주식회사 셀트리온	콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴
US8470318B2 (en)	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es)	2005-12-20	2014-01-24	Bristol-Myers Squibb Company	Composiciones y procedimientos de producción de una composición
US20070190057A1 (en)	2006-01-23	2007-08-16	Jian Wu	Methods for modulating mannose content of recombinant proteins
JP5199886B2 (ja) *	2006-01-26	2013-05-15	レコファーマアーベー	ウイルスの接着を阻害するための組成物および方法
EP3456351A1 (en) *	2006-04-05	2019-03-20	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX2009000349A (es) *	2006-07-13	2009-03-09	Wyeth Corp	Produccion de glicoproteinas.
CA2910619A1 (en)	2006-09-13	2008-03-20	Abbvie Inc.	Cell culture improvements
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
US20080145893A1 (en) *	2006-09-17	2008-06-19	Excellegene Sa	Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
AU2007317755A1 (en) *	2006-10-27	2008-05-15	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008069244A1 (ja) *	2006-12-05	2008-06-12	Kyowa Hakko Kogyo Co., Ltd.	糖蛋白質組成物の製造方法
AU2008240081A1 (en) *	2007-04-16	2008-10-23	Momenta Pharmaceuticals, Inc.	Methods related to cell surface glycosylation
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
US20090023186A1 (en) *	2007-07-22	2009-01-22	Excellgene Sa	Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
EP2188371B1 (en) *	2007-08-09	2017-12-20	Wyeth LLC	Use of perfusion to enhance production of fed-batch cell culture in bioreactors
TWI395593B (zh)	2008-03-06	2013-05-11	Halozyme Inc	可活化的基質降解酵素之活體內暫時性控制
RS65606B1 (sr) *	2008-03-06	2024-07-31	Halozyme Inc	Kompozicija rastvorljive hijaluronidaze
ES2517603T3 (es)	2008-04-07	2014-11-03	Bayer Healthcare, Llc	Procedimientos de producción recombinante de glucoproteínas
WO2009132130A2 (en)	2008-04-22	2009-10-29	The Rockefeller University	Methods of identifying anti-inflammatory compounds
PL2326720T3 (pl)	2008-09-15	2018-08-31	F. Hoffmann-La Roche Ag	Kompozycje i sposoby regulacji osmolarności komórki
EP2921501A1 (en) *	2008-10-20	2015-09-23	Abbvie Inc.	Isolation and purification of antibodies using Protein A affinity chromatography
BRPI0920572A8 (pt)	2008-10-20	2015-10-27	Abbott Lab	Inativação viral durante a purificação dos anticorpos
DK3037529T3 (da) *	2008-12-09	2019-05-20	Halozyme Inc	Udvidede opløselige ph20-polypeptider og anvendelse deraf
WO2010102262A1 (en) *	2009-03-06	2010-09-10	Halozyme, Inc.	Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
US9540426B2 (en)	2009-10-06	2017-01-10	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
EP3202785B1 (en)	2009-10-26	2024-05-08	F. Hoffmann-La Roche AG	Method for the production of a glycosylated immunoglobulin
ES2642629T3 (es)	2009-11-17	2017-11-17	E. R. Squibb & Sons, L.L.C.	Métodos para la producción mejorada de proteínas
WO2011068993A1 (en) *	2009-12-02	2011-06-09	Acceleron Pharma Inc.	Compositions and methods for increasing serum half-life of fc fusion proteins.
NZ601790A (en) *	2010-02-24	2014-03-28	Zymenex As	Process for production and purification of recombinant lysosomal alpha-mannosidase
JPWO2012017925A1 (ja)	2010-08-02	2013-10-03	協和発酵キリン株式会社	物質の製造方法
WO2012122625A1 (en)	2011-03-14	2012-09-20	National Research Council Of Canada	Method of viral production in cells
WO2012149197A2 (en)	2011-04-27	2012-11-01	Abbott Laboratories	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9631216B2 (en)	2011-04-29	2017-04-25	Biocon Research Limited	Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
US8883982B2 (en)	2011-06-08	2014-11-11	Acceleron Pharma, Inc.	Compositions and methods for increasing serum half-life
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
CN102839157A (zh) *	2012-07-12	2012-12-26	扬州大学	稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
KR20150043523A (ko)	2012-09-02	2015-04-22	애브비 인코포레이티드	단백질 불균일성의 제어 방법
NO2760138T3 (es)	2012-10-01	2018-08-04
WO2014062535A1 (en)	2012-10-15	2014-04-24	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
US20140106405A1 (en) *	2012-10-15	2014-04-17	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
EP2830651A4 (en)	2013-03-12	2015-09-02	Abbvie Inc	HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
CN105378480B (zh)	2013-07-04	2018-06-12	豪夫迈·罗氏有限公司	检测血清样品中抗药物抗体的干扰抑制性免疫测定
MX2016000123A (es)	2013-07-06	2016-07-14	Cadila Healthcare Ltd	Procedimiento mejorado para la produccion de anticuerpos monoclonales.
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
HRP20200100T1 (hr) *	2014-02-27	2020-04-03	F. Hoffmann - La Roche Ag	Modulacija rasta i glikozilacije stanica u rekombinantnoj proizvodnji glikoproteina
JP6652334B2 (ja)	2014-05-31	2020-02-19	Ｊｃｒファーマ株式会社	ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
MA40021A (fr) *	2014-06-03	2015-12-10	Lupin Ltd	Processus de culture cellulaire destiné à produire une protéine
US20160130324A1 (en)	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
KR102007930B1 (ko) *	2014-12-31	2019-08-06	주식회사 엘지화학	재조합 당단백질의 글리코실화 조절 방법
TWI797060B (zh)	2015-08-04	2023-04-01	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
BR112018010160A8 (pt)	2015-11-19	2019-02-26	Shire Human Genetic Therapies	inibidor da c1 esterase humana recombinante e usos do mesmo
CN108882740A (zh) *	2015-12-29	2018-11-23	N·V·努特里奇亚	含有不可消化寡糖的发酵配方物
EP3717656B1 (en) *	2017-11-30	2024-03-13	F. Hoffmann-La Roche AG	Process for culturing mammalian cells
US11634499B2 (en)	2018-11-13	2023-04-25	Janssen Biotech, Inc.	Control of trace metals during production of anti-CD38 antibodies
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
SG11202110972UA (en)	2019-12-06	2021-10-28	Regeneron Pharma	Anti-vegf protein compositions and methods for producing the same
EP4146686A2 (en)	2020-05-08	2023-03-15	Regeneron Pharmaceuticals, Inc.	Vegf traps and mini-traps and methods for treating ocular disorders and cancer
TW202432837A (zh)	2020-08-31	2024-08-16	美商再生元醫藥公司	用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
KR20230134117A (ko)	2021-01-20	2023-09-20	리제너론 파마슈티칼스 인코포레이티드	세포 배양물에서 단백질 역가를 개선시키는 방법
TW202323817A (zh)	2021-10-07	2023-06-16	美商再生元醫藥公司	Ｐｈ建模及控制之系統及方法
TW202331252A (zh)	2021-10-07	2023-08-01	美商再生元醫藥公司	Ｐｈ計校準與校正
WO2023167850A1 (en)	2022-03-02	2023-09-07	Regeneron Pharmaceuticals, Inc.	Manufacturing process for high titer antibody

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3926723A (en)	1974-08-08	1975-12-16	Massachusetts Inst Technology	Method of controllably releasing glucose to a cell culture medium
JPS5938488B2 (ja)	1979-05-07	1984-09-17	株式会社東芝	空気調和機
EP0097353B1 (en) *	1982-06-21	1990-08-16	The Wellcome Foundation Limited	Improved process for interferon production
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4724206A (en) *	1984-02-13	1988-02-09	Damon Biotech, Inc.	Protein production using hypertonic media
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
JPH0639919B2 (ja)	1985-08-29	1994-05-25	トヨタ自動車株式会社	過給機付き内燃機関の異常判別装置
GB8606386D0 (en) *	1986-03-14	1986-04-23	Celltech Ltd	Production of protein
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
WO1988001643A1 (en)	1986-08-29	1988-03-10	Endotronics, Inc.	Method of culturing cells
JPH01257492A (ja) *	1987-03-05	1989-10-13	Green Cross Corp:The	異種蛋白質の生産増強方法
IL87737A (en) *	1987-09-11	1993-08-18	Genentech Inc	Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH066054B2 (ja)	1987-10-15	1994-01-26	帝人株式会社	動物細胞の培養方法
CA1312030C (en) *	1987-11-18	1992-12-29	Brian Maiorella	Method to increase antibody titer
US5151359A (en) *	1988-05-19	1992-09-29	Mitsui Toatsu Chemicals Incorporated	Method for producing of human tissue type plasminogen activator
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
KR0132666B1 (en) *	1989-03-14	1998-04-14	Hitachi Kk	Method for controlling cultivation conditions for animal cells
JPH0396383A (ja)	1989-09-08	1991-04-22	Riso Kagaku Corp	画像形成装置
ATE236249T1 (de)	1989-09-12	2003-04-15	Hoffmann La Roche	Tfn-bindende proteine
US5096816A (en) *	1990-06-05	1992-03-17	Cetus Corporation	In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) *	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) *	1990-10-17	1990-11-28	Wellcome Found	Culture medium
GB2251249B (en) *	1990-12-28	1995-06-21	Mogam Biotech Res Inst	High-density medium for animal cell culture
AU3144193A (en) *	1991-11-21	1993-06-15	Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5447851B1 (en) *	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0620739A4 (en) *	1992-09-15	1997-01-15	Immunex Corp	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
JP3523293B2 (ja) †	1993-07-19	2004-04-26	住友製薬株式会社	インターフェロンの産生増強法
US5705364A (en) †	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
JP5515221B2 (ja) †	2008-01-28	2014-06-11	日油株式会社	ポリオキシエチレンソルビタン脂肪酸エステルの製造方法

1995
- 1995-06-06 US US08/469,348 patent/US5705364A/en not_active Expired - Lifetime
1996
- 1996-06-05 TW TW089111534A patent/TW516962B/zh not_active IP Right Cessation
- 1996-06-05 TW TW085106712A patent/TW426734B/zh not_active IP Right Cessation
- 1996-06-06 CZ CZ19973909A patent/CZ293719B6/cs not_active IP Right Cessation
- 1996-06-06 EP EP96918251A patent/EP0832189B2/en not_active Expired - Lifetime
- 1996-06-06 PT PT05017434T patent/PT1609853E/pt unknown
- 1996-06-06 KR KR1019970708954A patent/KR100496356B1/ko not_active Expired - Lifetime
- 1996-06-06 AT AT96918251T patent/ATE302266T1/de active
- 1996-06-06 JP JP9501638A patent/JPH11507523A/ja not_active Withdrawn
- 1996-06-06 DK DK05017434.1T patent/DK1609853T4/da active
- 1996-06-06 HU HU9900920A patent/HU226420B1/hu unknown
- 1996-06-06 EA EA199700364A patent/EA001215B1/ru not_active IP Right Cessation
- 1996-06-06 DK DK96918251T patent/DK0832189T4/da active
- 1996-06-06 GE GEAP19964011A patent/GEP20012519B/en unknown
- 1996-06-06 AT AT05017434T patent/ATE425245T2/de active
- 1996-06-06 DE DE69637867T patent/DE69637867D1/de not_active Expired - Lifetime
- 1996-06-06 SK SK1670-97A patent/SK282658B6/sk not_active IP Right Cessation
- 1996-06-06 EP EP05017434.1A patent/EP1609853B2/en not_active Expired - Lifetime
- 1996-06-06 AU AU60952/96A patent/AU717847B2/en not_active Expired
- 1996-06-06 WO PCT/US1996/009284 patent/WO1996039488A1/en active IP Right Grant
- 1996-06-06 CA CA002220684A patent/CA2220684C/en not_active Expired - Lifetime
- 1996-06-06 AR ARP960103001A patent/AR004940A1/es active IP Right Grant
- 1996-06-06 ES ES96918251T patent/ES2248812T5/es not_active Expired - Lifetime
- 1996-06-06 SI SI9630715T patent/SI0832189T2/sl unknown
- 1996-06-06 ZA ZA9604776A patent/ZA964776B/xx unknown
- 1996-06-06 RO RO97-02262A patent/RO120267B1/ro unknown
- 1996-06-06 NZ NZ310202A patent/NZ310202A/en not_active IP Right Cessation
- 1996-06-06 TR TR97/01543T patent/TR199701543T1/xx unknown
- 1996-06-06 IL IL12239896A patent/IL122398A/en not_active IP Right Cessation
- 1996-06-06 PL PL96323737A patent/PL185484B1/pl unknown
- 1996-06-06 ES ES05017434T patent/ES2324046T5/es not_active Expired - Lifetime
- 1996-06-06 UA UA97125856A patent/UA47428C2/uk unknown
- 1996-06-06 DE DE69635076T patent/DE69635076T3/de not_active Expired - Lifetime
- 1996-06-06 MY MYPI96002265A patent/MY113496A/en unknown
- 1996-06-06 CN CNB961944498A patent/CN1166772C/zh not_active Expired - Lifetime
- 1996-06-06 SI SI9630767T patent/SI1609853T2/sl unknown
- 1996-06-06 BR BR9609150A patent/BR9609150A/pt not_active Application Discontinuation
- 1996-10-07 SA SA96170351A patent/SA96170351B1/ar unknown
1997
- 1997-12-03 IS IS4626A patent/IS2614B/is unknown
- 1997-12-03 BG BG102101A patent/BG63213B1/bg unknown
- 1997-12-05 NO NO19975674A patent/NO322276B1/no not_active IP Right Cessation
- 1997-12-05 OA OA70153A patent/OA10753A/en unknown
1998
- 1998-02-12 AR ARP980100640A patent/AR011439A2/es unknown
2007
- 2007-02-28 JP JP2007050848A patent/JP4348376B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1166772C (zh)	2004-09-15
SI0832189T2 (sl)	2008-12-31
DK0832189T3 (da)	2005-11-21
SI0832189T1 (sl)	2006-02-28
DE69635076T3 (de)	2009-01-15
SI1609853T1 (sl)	2009-08-31
EA199700364A1 (ru)	1998-04-30
HU226420B1 (en)	2008-12-29
KR100496356B1 (ko)	2005-11-25
EP1609853B1 (en)	2009-03-11
NO322276B1 (no)	2006-09-04
SA96170351B1 (ar)	2006-07-04
EP0832189B1 (en)	2005-08-17
BG102101A (en)	1998-07-31
NO975674D0 (no)	1997-12-05
EP0832189B2 (en)	2008-07-09
AU6095296A (en)	1996-12-24
US5705364A (en)	1998-01-06
EP0832189A1 (en)	1998-04-01
NZ310202A (en)	1999-10-28
ES2324046T5 (es)	2020-09-14
EP1609853A1 (en)	2005-12-28
AU717847B2 (en)	2000-04-06
ATE302266T1 (de)	2005-09-15
ZA964776B (en)	1997-12-08
DE69637867D1 (de)	2009-04-23
AR011439A2 (es)	2000-08-16
SI1609853T2 (sl)	2020-07-31
CA2220684A1 (en)	1996-12-12
TW426734B (en)	2001-03-21
PL185484B1 (pl)	2003-05-30
ES2248812T3 (es)	2006-03-16
ATE425245T2 (de)	2009-03-15
HUP9900920A3 (en)	2001-06-28
EP1609853B2 (en)	2020-01-22
HUP9900920A2 (hu)	1999-07-28
DK1609853T3 (da)	2009-06-02
DK1609853T4 (da)	2020-04-06
ES2248812T5 (es)	2008-12-16
JPH11507523A (ja)	1999-07-06
BR9609150A (pt)	1999-02-23
PT1609853E (pt)	2009-06-09
PL323737A1 (en)	1998-04-14
JP2007190024A (ja)	2007-08-02
DE69635076D1 (de)	2005-09-22
UA47428C2 (uk)	2002-07-15
EA001215B1 (ru)	2000-12-25
DK0832189T4 (da)	2008-10-27
CZ293719B6 (cs)	2004-07-14
GEP20012519B (en)	2001-08-27
WO1996039488A1 (en)	1996-12-12
AR004940A1 (es)	1999-04-07
TR199701543T1 (xx)	1998-05-21
HK1017903A1 (en)	1999-12-03
MX9709452A (es)	1998-06-30
IS2614B (is)	2010-04-15
IS4626A (is)	1997-12-03
IL122398A0 (en)	1998-06-15
HK1087151A1 (en)	2006-10-06
NO975674L (no)	1998-02-06
JP4348376B2 (ja)	2009-10-21
SK167097A3 (en)	1998-07-08
BG63213B1 (bg)	2001-06-29
DE69635076T2 (de)	2006-06-01
CN1186514A (zh)	1998-07-01
SK282658B6 (sk)	2002-11-06
OA10753A (en)	2002-12-11
CA2220684C (en)	2002-11-12
RO120267B1 (ro)	2005-11-30
ES2324046T3 (es)	2009-07-29
MY113496A (en)	2002-03-30
KR19990022473A (ko)	1999-03-25
CZ390997A3 (cs)	1998-06-17
TW516962B (en)	2003-01-11

Publication	Publication Date	Title
AU717847B2 (en)	2000-04-06	Process for controlling sialylation of proteins produced by mammalian cell culture
US5721121A (en)	1998-02-24	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en)	2003-12-02	Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US6528286B1 (en)	2003-03-04	Mammalian cell culture process for producing glycoproteins
EP1092037B1 (en)	2005-12-28	Cell culture process for producing glycoproteins
CA2720610C (en)	2016-08-23	Methods of recombinant production of glycoproteins
HK1087151B (en)	2009-11-27	Process for controlling sialylation of proteins produced by mammalian cell culture
MXPA97009452A (es)	1998-10-30	Proceso para controlar la sialilacion de proteinas producidas por cultivo de celulas de mamiferos
HK1017903B (en)	2005-05-27	Process for controlling sialylation of proteins produced by mammalian cell culture

Legal Events

Date	Code	Title
2002-05-23	FF	Patent granted
2002-06-30	KB	Patent renewed
2002-07-25	KB	Patent renewed
2007-03-08	MM9K	Patent not in force due to non-payment of renewal fees